Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
Modified study designs to expand treatment options in personalised oncology: a multistakeholder view.
Le Tourneau C, André F, Helland Å, Mileshkin L, Minnaard W, Schiel A, Taskén K, Thomas DM, Veronese ML, Durán-Pacheco G, Leyens L, Rufibach K, Thomas M, Krämer A. Le Tourneau C, et al. Among authors: helland a. Eur J Cancer. 2023 Nov;194:113278. doi: 10.1016/j.ejca.2023.113278. Epub 2023 Aug 4. Eur J Cancer. 2023. PMID: 37820553 Free article. Review.
Overcoming barriers in biomarker testing. Letter to the Editor regarding: "ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe", by A. Bayle et al.
García-Foncillas J, Arnold D, Avouac B, Lassen U, Laurent-Puig P, Taieb J, Helland Å, Stenzinger A. García-Foncillas J, et al. Among authors: helland a. Ann Oncol. 2024 May 7:S0923-7534(24)00134-0. doi: 10.1016/j.annonc.2024.04.008. Online ahead of print. Ann Oncol. 2024. PMID: 38723866 No abstract available.
Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23-24, 2023.
Ringborg U, von Braun J, Celis J, Baumann M, Berns A, Eggermont A, Heard E, Heitor M, Chandy M, Chen CJ, Costa A, De Lorenzo F, De Robertis EM, Dubee FC, Ernberg I, Gabriel M, Helland Å, Henrique R, Jönsson B, Kallioniemi O, Korbel J, Krause M, Lowy DR, Michielin O, Nagy P, Oberst S, Paglia V, Parker MI, Ryan K, Sawyers CL, Schüz J, Silkaitis K, Solary E, Thomas D, Turkson P, Weiderpass E, Yang H. Ringborg U, et al. Among authors: helland a. Mol Oncol. 2024 Feb;18(2):245-279. doi: 10.1002/1878-0261.13575. Epub 2024 Jan 22. Mol Oncol. 2024. PMID: 38135904 Free PMC article.
IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results.
Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES, Haug Å, Fredvik Torkildsen C, Oppedal IA, Meltzer S, Flobak Å, Johansson KAM, Bjørge L, Hjortland GO, Dalhaug A, Lund JÅ, Gilje B, Grønlie Cameron M, Hovland R, Falk RS, Smeland S, Giercksky Russnes HE, Taskén K, Helland Å; InPreD Consortium; IMPRESS-Norway Consortium. Puco K, et al. Among authors: helland a. Acta Oncol. 2024 May 23;63:379-384. doi: 10.2340/1651-226X.2024.28322. Acta Oncol. 2024. PMID: 38779911 Free article.
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.
Taskén K, F Haj Mohammad S, Fagereng GL, Sørum Falk R, Helland Å, Barjesteh van Waalwijk van Doorn-Khosrovani S, Steen Carlsson K, Ryll B, Jalkanen K, Edsjö A, Russnes HG, Lassen U, Hallersjö Hult E, Lugowska I, Blay JY, Verlingue L, Abel E, Lowery MA, Krebs MG, Staal Rohrberg K, Ojamaa K, Oliveira J, Verheul HMW, Voest EE, Gelderblom H; PRIME-ROSE Consortium and the PCM4EU Consortium. Taskén K, et al. Among authors: helland a. Acta Oncol. 2024 May 23;63:385-391. doi: 10.2340/1651-226X.2024.34791. Acta Oncol. 2024. PMID: 38779910 Free article.
Small Cell Lung Cancer in Norway: Patterns of Care by Health Region and Survival Trends.
Nilssen Y, Brustugun OT, Fjellbirkeland L, Grønberg BH, Haram PM, Helbekkmo N, Helland Å, Wahl SGF, Aanerud M, Solberg S. Nilssen Y, et al. Among authors: helland a. Clin Lung Cancer. 2024 Apr 10:S1525-7304(24)00046-9. doi: 10.1016/j.cllc.2024.04.002. Online ahead of print. Clin Lung Cancer. 2024. PMID: 38692990 Free article.
Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study.
Miceli R, Eriksson H, Lo Russo G, Alfieri S, Moksnes Bjaanæs M, Pietrantonio F, De Cecco L, Prelaj A, Proto C, Franzén J, McDonnell D, Berenguer Pina JJ, Beninato T, Mazzeo L, Giannatempo P, Verzoni E, Crown J, Helland Å, Eustace A. Miceli R, et al. Among authors: helland a. Acta Oncol. 2024 Apr 21;63:213-219. doi: 10.2340/1651-226X.2024.24179. Acta Oncol. 2024. PMID: 38647024 Free article.
276 results